Replies to post #226234 on Biotech Values

[DewDiligence]

ENTA—EDP-305 slide sets:

https://s22.q4cdn.com/306858242/files/doc_presentations/2019/09/EDP305_TOPLINE-DATA_for-website.pdf (ARGON-1 topline data)

https://s22.q4cdn.com/306858242/files/doc_presentations/2019/09/FXR_DataComparison-_Final.pdf (FXR comparisons)

[DaveAu]

ENTA—After listening to the CC and further contemplating the EDP-305 dataset reported today, I think ENTA should strongly consider switching from EDP-305 to the company's backup FXR compound.

Is there any reason to believe their backup compound won't have the same problem? Maybe they should consider abandoning FXR.

[lgonber]

Hello Dew, I know you are a long term investor in ENTA. I used to own the stock a few years ago I bought at $40s but sold at $100.
Do you think after yesterday’s news it is good time to get back in? I know next week is data for Phase 2a data on EDP-938. Would be an opportunity to get back in before data release? Or better wait? Thanks for your wait

[DewDiligence]

Musings on ENTA’s EDP-305 NASH program:

Regrettably (IMO), ENTA is continuing the EDP-305 NASH program and intends to use doses of 1.5mg and 2.0mg in the planned phase-2b trial.

Inasmuch as the 2.5mg dose in the phase-2a trial caused undue pruritis (#msg-151356515, #msg-151358332), and the 1.0mg dose in the phase-2a trial had insufficient efficacy (as monotherapy), testing doses of 1.5mg and 2.0mg in phase-2b could be threading a needle with no eye (#msg-151358158).

If it were up to me, I would bag the EDP-305 NASH program* and move ahead full steam with EDP-297 (#msg-152423076).

With $400M in cash and no debt (#msg-152422891), ENTA need not fall prey to Zebra’s Law.

--
*EDP-305 has an in-progress phase-2 in PBC, but this trial is not costing ENTA much money.